DAVID GRANOVSKY

Posts Tagged ‘trade’

International Stem Cell Corporation Signs Financing Agreement – Yahoo! Finance

In BUSINESS OF STEM CELLS on May 6, 2010 at 1:02 pm

International Stem Cell Corporation Signs Financing Agreement

Press Release Source: International Stem Cell Corporation On Wednesday May 5, 2010, 7:30 am EDT

OCEANSIDE, Calif.–BUSINESS WIRE–International Stem Cell Corporation OTCBB:ISCO, http://www.intlstemcell.com, today announced it has entered into a definitive agreement dated May 4, 2010 ‘the Agreement” with Socius CG II, Ltd. “Socius”, pursuant to which Socius has committed to purchase a single tranche of up to $10 million in non-convertible Series F Preferred Stock the “Preferred Stock” from ISCO.

The Company issued a warrant to purchase $13,500,000 worth of the Company’s Common Stock, the exercise price of the warrant being determined by the closing bid price for the Company’s Common Stock on the trading day immediately preceding the date the Company initiates the sale of the Series F Preferred…

via International Stem Cell Corporation Signs Financing Agreement – Yahoo! Finance.

Advertisements

THE EMBRYONIC STEM CELL HOAX: A HISTORY OF THE GERON SCANDAL

In ALL ARTICLES on February 20, 2010 at 11:43 pm

02/20/2010

THE EMBRYONIC STEM CELL HOAX: – A HISTORY OF THE GERON SCANDAL


For six years, the American people’s understanding of stem cells has been overwhelmed by rampant misinformation and deception. We were led to believe the future of medicine lies in Embryonic Stem Cells (ESC) and that Repair (adult) Stem Cells (RSC) are “snake oil.”
These skewed stories of ESC hope and RSC failure intentionally misled the American people in general and forced spinal cord patients to pay for the false-hope of ESC treatments in order to line the pockets of the  ESC promoters.

 

PFIZER BUYS INTO ADULT/REPAIR STEM CELL COMPANY ATHERSYS

In BUSINESS OF STEM CELLS, VICTORIES & SUCCESS STORIES on December 21, 2009 at 1:18 pm

PFIZER BUYS STEM CELL COMPANY ATHERSYS & Acquires Stem-Cell Therapy Product MulitStem

By ANDREW POLLACK

Published: December 21, 2009 – Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in (ADULT or REPAIR)  stem cells.

Why is this controversial? There are no embryos involved.  These are adult or repair stem cells.  There are thousands of clinical trials and tens of thousands of scholarly papers showing their safety and efficacy.  If a new cancer drug comes out that is not through all stages of clinical trials it is not controversial; why is this? -dg

Athersys’s cells, derived from human bone marrow (these are Adult or Repair Stem Cells, not embryonic – dg), have not yet been tested in people with inflammatory bowel disease, a term that encompasses ulcerative colitis and Crohn’s disease. But the product, called MultiStem, is in early human testing as a treatment for heart attacks and for cancer patients receiving bone marrow transplants.

Pfizer will have the rights to develop Athersys’s cells to treat inflammatory bowel diseases, the companies are expected to announce on Monday.

Irritable Bowel Syndrome + Crohn's Disease Treatment Info

CLICK PICTURE for Irritable Bowel Syndrome, Colitis, Crohn's Disease Treatment Info

STOCK ALERT

Pfizer will pay Athersys $6 million initially and up to $105 million in the future.  Athersys [ NASDAQ:ATHX ] soared as high as $3.95 today on the news and has leveled off to $2.80, a 180% gain by noon today.)

via Pfizer Acquires MultiStem, a Therapy Based on Stem Cells – NYTimes.com.

For more info:

Aastrom requests delisting extension

In BUSINESS OF STEM CELLS on October 8, 2009 at 3:19 pm

Aastrom Biosciences Inc. will request hearing to avoid Nasdaq delisting – By Gabe Nelson

https://i0.wp.com/www.aastrom.com/images/AboutUs_4-09.gif

Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of chronic cardiovascular diseases.

Ann Arbor-based Aastrom Biosciences Inc. (Nasdaq: ASTM) is in danger of being removed from the Nasdaq Stock Exchange because the company’s stock price has remained below the listing threshold of $1, the company said today.

Aastrom plans to request a hearing with Nasdaq by Oct. 13 to request an extension, according to a statement.

Aastrom produces stem cell-based therapeutics to repair human tissue. The stem cells, grown from a patient’s bone marrow, are used to treat conditions such as chronic cardiovascular diseases.

The company first faced delisting in December 2007 and received a 180-day extension the following June.

Though Aastrom’s stock price stayed below $1, the company remained listed because of a temporary change to Nasdaq policy. The exchange suspended threshold requirements from last October until this July because so many companies saw their stock fall below $1 during the recession.

The most recent extension, granted in July, gave Aastrom until Oct. 1.

The exchange could choose to grant Aastrom an additional 180 days, or until March 31, 2010, to meet listing criteria.

The company’s stock price would need to close at $1 or above for 10 consecutive days of trading.

It opened Wednesday at 42 cents.

via Aastrom Biosciences Inc. will request hearing to avoid Nasdaq delisting – Detroit News and Information – Crain’s Detroit Business.

TOP STEM CELL STOCK NEWS TODAY

In BUSINESS OF STEM CELLS on September 28, 2009 at 4:04 pm

SWVL, EVFL, GOIG, SCII, September 28 Stocks to Watch from otcpicks.com

Emailwire – ‎7 hours ago‎
Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell

Not knowing what’s ahead, we look to futurists to help figure it out

Philadelphia Inquirer – Carol M. Ostrom – ‎6 hours ago‎
Dr. Chuck Murry, a University of Washington researcher who works with heart muscles and stem cells, doesn’t call himself a futurist, but adds: “I think we

Merkel wins German election

Nature.com (subscription) – ‎9 hours ago‎
[The Free Democrats] have a distinctly liberal approach in hot-button areas such as genetically modified crops and stem cells. … If the Free Democrats,

2009 Annual Financial Report

Sydney Morning Herald – ‎11 hours ago‎
Biocell was subsequently renamed Australian Stem Cell Healthcare Pty Ltd and is now the largest private cord blood bank in Australia.

Primera Bioscience Research Inc. Announces 2009 Financing

PR-USA.net (press release) – ‎10 hours ago‎
The Corporation currently has one project which is to collaborate with and provide $300000 of funding for certain brain tumour and stem cell research being

Dr. Stockpick Announces Daily Stock Watch – GFGU, PWRM, SCII

World Stock Wire (press release) – ‎8 hours ago‎
Today’s alerts include: getfugu, Inc. (OTCBB: GFGU), Power3 Medical Products, Inc. (OTCBB: PWRM), and Stem Cell Therapy International, Inc. (OTCBB: SCII).

BUYINS.NET: Naked Short Web Site Announces DNE, OSIR, GBGD Have

Trading Markets (press release) – ‎5 hours ago‎

There is no longer a failure to deliver in shares of DNE Osiris Therapeutics, Inc. (NASDAQ: OSIR), a stem cell therapeutic company, develops products to

Advanced Cell Technology Announces Proxy Results | Reuters

In BUSINESS OF STEM CELLS on September 16, 2009 at 2:33 pm

WORCESTER, Mass.–(Business Wire)– Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) announced today that shareholders have approved each proposal in the Company`s proxy statement dated August 5, 2009.

As a result, the 2005 Stock Incentive Plan has been amended to increase the total number of shares available for issuance and the certificate of incorporation has been amended to increase the authorized shares eligible for issuance by the Company.

“We are pleased that shareholders have elected to approve each of the proposals in the proxy, supporting the Company`s efforts to further develop its stem cell technology platform,” said William M. Caldwell IV, the Company`s Chairman and Chief Executive Officer.

“We remain focused on submitting an IND for the RPE program to the FDA for approval to commence a Phase I Clinical Trial prior to the end of the year.”

via Advanced Cell Technology Announces Proxy Results | Reuters.

Are you or a loved one interested in receiving stem cell treatment? For free treatment information, please fill out our treatment form or email don@repairstemcells.org and just put Therapy in the subject box.

AMIE,DSCO,SPDE,SCII OTC Picks Sept 14 – Stocks to Watch

In BUSINESS OF STEM CELLS on September 14, 2009 at 6:28 pm

STEM CELL THERAPY INTERNATIONAL (OTCBB: SCII | Quote | Chart | News | PowerRating) “Up 69.81% on Friday”

Detailed Quote: http://www.otcpicks.com/quotes/SCII.php

Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It provides allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company's stem cell biological solutions can be used to alleviate the side effects of chemotherapy

. Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted from umbilical cord blood. It intends to offer biological solutions containing stem cell products primarily in the United States to universities, institutes, and privately funded laboratory facilities for research purposes and clinical trials. The company was incorporated in 2004 and is headquartered in Tampa, Florida.

via AMIE,DSCO,SPDE,SCII OTCPicks.com: AMIE, DSCO, SCII, SPDE, September 14 Stocks to Watch from OTCPicks.com.

GCKO,GVBP,NPDT,OGNG Wall Street News Alert

In BUSINESS OF STEM CELLS on September 14, 2009 at 11:06 am
NovaGen_Image01

GENova Biotherapeutics

GENova Biotherapeutics, Inc. (OTCBB: GVBP | Quote | Chart | News | PowerRating) up 17.8% on 39 million shares traded.

breast reconstructionOn Sept 10, 2009 GENova Biotherapeutics, Inc. a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, recently announced it has filed a patent for a potential blockbuster drug target that combats breast cancer. The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

breast cancer cell

breast cancer cell

This novel approach – using proteins to stop cancer – is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.

chemotherapy

chemotherapy

“This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy,” says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

via GCKO,GVBP,NPDT,OGNG Wall Street News Alert: Stock on the Move: GCKO – September 10, 2009.

Geron Clone? SEC says CellCyte Genetics lied to inflate stock price

In BUSINESS OF STEM CELLS on September 9, 2009 at 7:23 am

SEC: Bothell biotech firm lied to inflate stock price

By LEVI PULKKINENSEATTLEPI.COM STAFF

Federal regulators filed complaints Tuesday against (CellCyte Genetics Corp.) a Bothell-based biotechnology company, saying management of the firm defrauded investors by inflating claims about a stem cell technology it was developing.

In a statement to media, a Securities and Exchange Commission spokesperson alleged that CellCyte Genetics Corp. misled investors into believing the technology was headed for human trials when in fact the company’s product remained in the early stages of development.

SEC officials allege stock promoters hired by CellCyte then spread the false information to investors, driving the stock price to $7.50-a-share before it plummeted back to less than a dime.

The complaints, filed in federal district court in Seattle, allege that in multiple public filings with the SEC and in other investor materials CellCyte falsely claimed it had received U.S. Food and Drug Administration approval to begin human clinical trials with a special stem cell compound to repair the heart, the spokesperson said.

The SEC alleges that CellCyte did not know how to properly formulate the stem cell compound, had never tried experiments with the compound to repair organs and had not satisfied any of the FDA requirements to begin human clinical trials.

In addition to the corporation, the SEC named in the suit CellCyte’s then-Chief Scientific Officer Ronald Berninger, of Mukilteo, who allegedly approved or participated in the drafting of false and misleading statements.

CellCyte and Berninger agreed to a settlement, without admitting or denying the SEC’s allegations, in which they each consented to a permanent injunction, according to the news statement. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.

Speaking Tuesday, CellCyte attorney Steve Fogg noted that the company did not pay a financial penalty and emphasized that the decision to settle with the SEC carried no admittion of guilt. Fogg said the company is no longer pursuing the technology at issue in the complaint.

“Given that they’re moving forward with a separate technology, it just made sense to settle this lawsuit,” said Fogg, adding that “nobody cashed in on CellCyte stock who was an officer or director of CellCyte.”

In a separate action, the SEC has accused ex-CellCyte CEO Gary Reys, of Freeland, of approving the company’s fraudulent SEC filings. Federal regulators are seeking injunctive relief, a monetary penalty and an order barring Reys from serving as an officer or director of a public company.

A few other sources of this info:

SEC Whacks CellCyte Genetics & Bosses
Courthouse News Service – ‎29 minutes ago‎ – SEATTLE (CN)
SEC: Bothell biotech co lied about breakthrough to inflate stock price
KOMO News – Martha Kang – ‎6 hours ago‎ – SEATTLE
SEC accuses CellCyte Genetics, former top execs of fraud
TechFlash – Eric Engleman – ‎8 hours ago‎
SEC Charges CellCyte With Stem Cell Fraud
Xconomy – Luke Timmerman – ‎14 hours ago‎
SEC sues CellCyte, former execs for lying to investors
FierceBiotech – Calisha Myers – ‎14 hours ago‎
SEC accuses CellCyte, execs of fraud
Bizjournals.com – ‎14 hours ago‎
SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping
PharmaLive.com (press release) – ‎15 hours ago‎
BRIEF-US SEC charges CellCyte for fraudulently touting stem cell
Forbes – Julie Vorman – ‎16 hours ago‎
SEC sues CellCyte and its executives
Seattle Times – ‎17 hours ago‎

BCLI,CVIT,CVITE,NWMT,NPHC – NewMarket Technology – September 2, 2009

In BUSINESS OF STEM CELLS on September 3, 2009 at 10:24 am

Weston, FLA, Sep 02, 2009 (M2 PRESSWIRE via COMTEX) — NPHC | Quote | Chart | News | PowerRating — Wall Street News Alert's “stocks to watch” this morning are: NewMarket Technology, Inc. (OTC: NWMT), Cavit Sciences Inc. (OTC: CVIT), BrainStorm Cell Therapeutics Inc (OTCBB: BCLI | Quote | Chart | News | PowerRating) and Nutra Pharma Corp. (OTCBB: NPHC).

via BCLI,CVIT,CVITE,NWMT,NPHC Wall Street News Alert: Stock Watch for Wednesday: NewMarket Technology – September 2, 2009.

%d bloggers like this: